Objective: To compare overall patient satisfaction of migraine management pre- and post- Sumatriptan treatment with 50mg tablets versus non-triptan compounds (prescription or OTC) in the treatment of migraine headaches. Methods: We performed an open-label, observational study using historical baseline data and a prospective treatment phase in order to assess patient treatment satisfaction pre- and post- triptan treatment with 50mg Sumatriptan tablets and preference for Sumatriptan compared to previous non-triptan therapy for migraine headache over a three month period. Results: Of the 21 patients initially enrolled in the study, 15 completed the study (1 never had a migraine, 2 – never returned questionnaires, 3 Sumatriptan failures). 13 of 15 patients preferred sumatriptan, 1 preferred their prior therapy, and 1 stated no preference. Compared to their prior therapy, fewer ER visits and office visits for migraine were utilized by patients during the study. Among those patients who were employed, there were fewer worked days missed because of migraine and fewer days working with migraine. Conclusion: Compared to non-triptan therapy, oral Sumatriptan 50 mg therapy results in increased patient satisfaction, decreased medical service utilization, decreased sick-days/days missed from work, and a decrease in the number of days having to work with a migraine.